851014-95-4

Usage

Uses

Given the provided information, the specific uses of (5-amino-2-butyl-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]-,oxalate are not explicitly detailed. However, based on the presence of common functional groups found in biologically active compounds, we can infer potential applications:
Used in Pharmaceutical Industry:
(5-amino-2-butyl-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]-,oxalate could be used as a pharmaceutical agent for its potential biological activity, which may be attributed to the presence of the amino and benzofuran groups. These groups are often found in compounds with therapeutic effects, and further research would be necessary to explore and confirm its specific medicinal properties and uses.
Used in Research and Development:
In a research context, (5-amino-2-butyl-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]-,oxalate might serve as a starting material or a structural component in the synthesis of new compounds with potential applications in various fields such as medicine, agrochemistry, or materials science. Its unique structure could be exploited to develop new drugs or probe the interactions of biological systems with novel chemical entities.

Upstream product

• 36421-15-5 dibutyl-(3-chloro-propyl)-amine 
• 526196-92-9 (2-n-butyl-benzofuran-5-yl)-acetamide 
• 1278585-69-5 N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)acetamide 
• 144-62-7 oxalic acid 
• 1278585-66-2 2-n-butyl-3-(4-hydroxybenzoyl)-5-acetamidobenzofuran 
• 1278585-63-9 2-n-butyl-3-(4-methoxybenzoyl)-5-acetamidobenzofuran 
• 111-92-2 dibutylamine 
• 65136-52-9 4-(3-chloropropoxy)benzoic acid 
• 65136-48-3 4-(3-chloropropoxy)benzoic acid chloride 
• 526196-90-7 2-n-butyl-5-aminobenzofuran hydrochloride 
• 1365546-06-0 3-[4-(3-chloropropoxy)benzoyl]-2-n-butylbenzofuran-5-yl-1H-isoindole-1,3(2H)dione 
• 1365546-05-9 2-(-2-butyl-1-benzofuran-5-yl)-1H-isoindole-1,3(2H)dione 
• 6153-56-6 oxalic acid dihydrate 
• 1365546-07-1 C₃₈H₄₄N₂O₅ 

Downstream Products

• 141644-91-9 (5-amino-2-butyl-benzofuran-3-yl)-[4-(3-dibutylamino-propoxy)-phenyl]-methanone 
• 141625-93-6 dronedarone hydrochloride 
• 141626-57-5 N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide 
• 141626-36-0 dronedarone 

Relevant academic research and scientific papers

2-butyl-3 - (4-substituted propoxy benzoyl) - 5-substituted aminobenzofuran and its application

The invention discloses 2-n-butyl-3-(4-subsitituted propylbenzoyl)-5-substituted amino benzofuran and application thereof. The 2-n-butyl-3-(4-subsitituted propylbenzoyl)-5-substituted amino benzofuran can be used for preparing dronedarone and pharmaceutic

Preparation method of dronedarone hydrochloride key intermediate

The invention relates to a preparation method of a dronedarone hydrochloride key intermediate. The preparation method comprises following steps: 1) 2-butyl-benzofuran-5-ylamine hydrochloride and phthalic anhydride are subjected to reflux reaction under alkaline conditions so as to protect amino groups; and 2) 4-[3-(dibutyl amino) propoxy] benzoic acid is added into Eaton's reagent for stirring reaction, an intermediate 1 is added, temperature is controlled for reaction, a free amine is obtained via treatment, and the free amine and oxalic acid are subjected to salt forming reaction so as to obtain compound IV 5-amino-2-n-butyl-3-[4-(3-n-dibutyl aminopropoxy) benzoyl]benzofuran oxalate. The dronedarone hydrochloride key intermediate is prepared by taking 2-butyl-benzofuran-5-ylamine hydrochloride as the starting raw material; production of the dronedarone free amino is high in selectivity, and high in yield; fewer steps are needed; so that the preparation method is suitable for industrialized production.

Identification and characterization of potential impurities of dronedarone hydrochloride

Six potential process related impurities were detected during the impurity profile study of an antiarrhythmic drug substance, Dronedarone (1). Simple high performance liquid chromatography and liquid chromatography-mass spectrometry methods were used for the detection of these process impurities. Based on the synthesis and spectral data (MS, IR, 1H NMR, 13C NMR, and DEPT), the structures of these impurities were characterized a s 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butylbenzofuran (impurity I); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)-methanesulfonamide (impurity II); N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-1-chloromethanesulfonamide (impurity III); N-{2-propyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl} - methanesulfonamide (impurity IV); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy) benzoyl)benzofuran-5-yl)-formamide (impurity V); and (2-butyl-5-((3- (dibutylamino)propyl)amino)benzofuran-3-yl)(4-(3- (dibutylamino)propoxy)phenyl) methanone (impurity VI). The synthesis and characterization of these impurities are discussed in detail.

An improved scalable route to pure dronedarone hydrochloride

An efficient scalable synthesis for dronedarone hydrochloride (2) via Friedel-Craft acylation of 2-(-2-butyl-1-benzofuran-5-yl)-1H-isoindole-1,3(2H) dione (12) with 4-(3-chloropropoxy) benzoic acid (13) in good yield and high purity has been developed by using Eaton's reagent instead of hazardous and toxic metal halide catalyst like AlCl3 or SnCl4.

Process for obtaining dronedarone

The present invention provides a process for obtaining dronedarone or salts thereof characterized in that in an organic phase comprising one or more non-polar solvents, 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butyl-benzofuran is reacted with methane sulfonyl chloride without the addition of a base. The invention also provides a process for obtaining intermediates of dronedarone environmentally friendly and industrially viable..

IMPROVED PROCESSES FOR OBTAINING HIGH PURITY OF DRONEDARONE HYDROCHLORIDE

Improved processes for obtaining high purity of Dronedarone hydrochloride (chemically known as N-(2-buty1-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide hydrochloride) are provided.

PROCESS FOR OBTAINING DRONEDARONE

The present invention provides a process for obtaining dronedarone or salts thereof characterized in that in an organic phase comprising one or more non-polar solvents, 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butyl-benzofuran is reacted with methane sulfonyl chloride without the addition of a base. The invention also provides a process for obtaining intermediates of dronedarone environmentally friendly and industrially viable.

PROCESS FOR N-[2-n-BUTYL-3-[4-[3-(DI-n-BUTYLAMINO) PROPOXY]ENZOYL]BENZOFURAN-5-YL]METHANESULFONAMIDE HYDROCHLORIDE

The present invention provides a process for preparing compound of formula (I),

PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES

The invention relates to process for the preparation of benzofuran derivative and intermediates thereof. More particularly, it relates to processes for the preparation of dronedarone or pharmaceutically acceptable acid addition salts thereof in crystalline form. The invention also relates to pharmaceutical compositions that include the dronedarone hydrochloride in crystalline form substantially free from disulfonamide impurity.